ArticleSisli Etfal Hastanesi tip bulteni2022
Relationship Between Thyroid-Stimulating Hormone Level and Aggressive Pathological Features of Papillary Thyroid Cancer.
Article in Sisli Etfal Hastanesi tip bulteni, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 14 citations in OpenAlex.
- The value of C-TIRADS combined with multidimensional indicators in the diagnosis of papillary thyroid carcinoma.Gland surgery · 2025Article
- Serum Biomarkers in Thyroid Malignancies: Evaluating Thyroid-Stimulating Hormone Receptor (TSHR) and Vascular Adhesion Protein-1 (VAP-1) as Potential Diagnostic Biomarker.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Network toxicological insights into DEHP exposure and thyroid cancer development and progression.Frontiers in oncology · 2025Article
- Construction and validation of a predictive model for lymph node metastasis in patients with papillary thyroid carcinoma.Frontiers in endocrinology · 2025Article
- Construction of a predictive model for cervical lymph node metastasis in papillary thyroid carcinoma.Frontiers in oncology · 2025Article
- Impaired thyroid hormone sensitivity increases the risk of papillary thyroid cancer and cervical lymph node metastasis.Endocrine · 2024Article
- Navigating Thyroid Dysfunction and Comorbidities Among University Students in Abbottabad, Pakistan - A Cross-Sectional Evaluation of Screening Tool for Thyroid Dysfunction.International journal of general medicine · 2023Article
- Association between thyroid stimulating hormone levels and papillary thyroid cancer risk: A meta-analysis.Open life sciences · 2023Article
- Clinicopathological features of papillary thyroid carcinoma in HIV-infected patients.Frontiers in oncology · 2023Article
- Predictive Factors Affecting the Development of Central Lymph Node Metastasis in Papillary Thyroid Cancer.Sisli Etfal Hastanesi tip bulteni · 2022Article
- Prediction Model of Cervical Lymph Node Metastasis in Papillary Thyroid Carcinoma.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Thyroid-stimulating hormones (TSHs) are associated with the risk of differentiated thyroid cancer. The relationship between pre-operative TSH levels and aggressive features is unclear. We aimed to evaluate the relationship between pathological features of papillary thyroid carcinoma (PTC) and high TSH levels. Methods: Patients who were operated between 2012 and 2017 and who were found to have PTC in their pathology were included in the study. The relationship between TSH and the features of tumor aggressiveness was evaluated in the patients. Results: Of the 132 patients, TSH level was significantly higher in those with lymphovascular invasion than those without (p=0.048), in those with central metastases than in those without (p=0.014), and in those with extrathyroidal spread than in those without (p=0.003). When patients were categorized into four 25% quartiles according to TSH (mUI/mL) level; the rate of extrathyroidal invasion increased as the TSH level increased, and the level was significantly higher in quartile 1 than the others, with significant difference (p=0.030). Conclusion: Pre-operative increase in TSH level is associated with an increased risk of extrathyroidal spread and central lymph node metastasis. TSH level may be a pre-operative valuable predictive factor for patients' risk of central metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.